NaviFUS Launches Neuronavigation-guided Clinical Trial to Open the Blood-Brain-Barrier for Combination FUS-Bevacizumab Therapy in rGBM Patients

Genovate Biotech (TPEX:4130) subsidiary and Taiwan-based focused ultrasound (FUS) manufacturer NaviFUS Corporation is pleased to announce the start of its clinical trial (NCT04446416) for the combination of FUS plus bevacizumab therapy. Researchers at Linkou Chang Gung Memorial Hospital are investigating the use of Neuronavigation-guided FUS to repeatedly and temporarily open the blood-brain barrier (BBB) and enhance bevacizumab's efficacy in patients with recurrent glioblastoma (rGBM). To date, the first patient has been enrolled and is undergoing treatment.


Led by neurosurgeon Dr. Kuo-Chen Wei at Linkou Chang Gung Memorial Hospital, the clinical trial will evaluate the safety and preliminary efficacy of repeated FUS-induced BBB opening with bevacizumab using the company's NaviFUS System. NaviFUS System utilizes neuronavigation and prior patient CT/MR images to guide the FUS energy. Additionally, the system includes a real-time acoustic emissions monitoring function that can personalize a safe and optimal level of FUS energy treatment for each patient.


The study plans to enroll six rGBM patients who will undergo biweekly bevacizumab treatment. Per the clinical trial protocol, patients will receive FUS treatment with every bevacizumab dose up to the 34th week or until further disease progression. The first patient enrolled in August, and preliminary monitoring from the initial bevacizumab with FUS treatments have shown the patient's condition is stable with no adverse events.


"The goal of the study is to investigate the possibility of delivering a large molecular weight drug to the brain in higher concentrations using FUS technology," said NaviFUS Chief Executive Officer Arthur Lung, Ph.D. "To our knowledge, this is the first time large molecular bevacizumab delivered into the brain in significant quantities. Should we observe positive results from the study, we expect it will be a good model for further extension to other biologicals, antibodies, antibody-drug conjugates, and cell therapies. This trial is an important step in meeting the goal of our company, which uses an innovative and safe way to help treat the central nervous system (CNS) diseases in the future."


This clinical trial is also funded in part by the Focused Ultrasound Foundation. "This trial uses an innovative device to open the blood-brain barrier repetitively," says Foundation Chairman Neal F. Kassell, MD. "It is an important step in the path to developing novel approaches for delivering a variety of therapeutic agents to the brain. This trial can facilitate the treatment of primary and metastatic brain tumors as well as neurodegenerative diseases for which there are few other treatments, including Parkinson's, Alzheimer's, and ALS."


https://www.prnewswire.com/news-releases/navifus-launches-neuronavigation-guided-clinical-trial-to-open-the-blood-brain-barrier-for-combination-fus-bevacizumab-therapy-in-rgbm-patients-301128260.html


https://www.fusfoundation.org/news/new-clinical-trial-for-focused-ultrasound-in-glioblastoma


Location: 台灣

Comments

Post a Comment

Popular posts from this blog

NaviFUS eyeing next year to launch new NAVIRFA Scope product in Taiwan and U.S. market

Image
 NaviFUS, a subsidiary of Genovate Biotech (4130), is developing a Radiofrequency Ablation (RFA) product called the NAVIRFA Scope. Simultaneous applications for regulatory approval are underway in both the United States and Taiwan.  NaviFUS has already submitted a pre-market notification 510(k) application to the U.S. FDA on December 4, 2020, and it expects to receive approval as early as mid-2021; at the same time, NaviFUS will also seek regulatory approval in Taiwan for the NAVIRFA Scope, and it has previously signed a sales distributor contract with UniPharma on October 31, 2020. NaviFUS believes that regulatory approval can also be acquired in 2021 and thus begin commercial sales in Taiwan.  There are approximately one million liver cancer patients worldwide, and the Asia-Pacific market has an annual growth rate of 12.67%; it is a market that urgently needs new treatment methods. In comparison with other first-line treatments such as surgery and hepatic artery embolization, RFA has
Read more

NaviFUS highlights clinical trial data and device capabilities at virtual International Focused Ultrasound Symposium

Image
 TAIPEI, Nov. 27, 2020 /PRNewswire/ -- The 7th International Focused Ultrasound Symposium organized by the U.S. Focused Ultrasound Foundation took place from 11/9 to 11/13 in virtual format this year due to the Covid-19 epidemic. During the 5-day conference, participants presented and exchanged information on the newest developments and applications of non-invasive Focused Ultrasound (FUS) technology. Likely the largest FUS event of the year, the virtual conference hosted over 1,700 industry, medical, and academic professionals from all over the world. NaviFUS was heavily involved in the virtual conference this year; posting 3 recorded oral presentations and 1 poster presentation, and also participating in 2 panel discussions during the first two days of the conference. Notable highlights from NaviFUS at the conference include its Epilepsy neuromodulation clinical trial that just finished its safety phase, preliminary progress from its FUS combined with Avastin in rGBM patients clinica
Read more

魏國珍醫師於SNO神經腫瘤學會/FUS聚焦式超音波協會網路研討會中介紹最近臨床發現

Image
 2020 年 10 月 13 日，SNO神經腫瘤學會/FUS基金會舉辦關於聚焦式超音波破壞血腦屏障（BBBD） 的網路研討會。 目前有多項計畫與正在進行的臨床試驗，在研究這種迅速發展的方法，來增強小分子、抗體和細胞向腦腫瘤的傳遞。 此網路研討聚集製藥公司及生物技術公司，提供研究人員們一起推動這項技術，以及有關使用聚焦式超音波破壞血腦屏障（BBBD）於腦腫瘤患者上的最新機會與挑戰資訊。 五位領域專家簡報，隨後進行問答討論。  觀看更多>
Read more